Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine

Trial Profile

Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azeliragon (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms STEADFAST
  • Sponsors vTv Therapeutics LLC.
  • Most Recent Events

    • 15 Jul 2019 According to vTv Therapeutics media release, data from this study will be presented at the 2019 Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, July 14 to 18, 2019.
    • 28 Mar 2019 According to a vTv Therapeutics LLC media release, results from this trial will be presneted at the 14th International Conference on Alzheimer's & Parkinson's Diseases.
    • 24 Oct 2018 According to a vTv Therapeutics LLC media release, post-hoc subgroup analysis data was presented at the 11th Clinical Trials on Alzheimers Disease (CTAD) conference 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top